<p>Aquestive Therapeutics, Inc.（纳斯达克代码：AQST - 免费报告）- HC Wainwright 在 2023 年 3 月 10 日星期一发布的研究报告中对 Aquestive Therapeutics 的 2026 财年每股收益进行了预测。HC Wainwright 的分析师 R. Selvaraju 预计该公司将发布每股收益（$0.56）。HC Wainwright 对该股票给予 “买入” 评级，目标价为 10.00 美元。市场普遍预计 Aquestive Therapeutics 当前全年的每股收益为（$0.46）。</p>
<p>获取 <strong>Aquestive Therapeutics</strong> 的提醒：</p>
<p>Aquestive Therapeutics（纳斯达克代码：AQST - 获取免费报告）最近在 2023 年 3 月 5 日星期三发布了季度财报。该公司报告季度每股收益为（$0.19），低于分析师普遍预期的（$0.14），差距为（$0.05）。该公司在本季度的收入为 1187 万美元，而分析师预期为 1311 万美元。</p>
<p>其他一些股票研究分析师最近也对该股票发表了看法。Cantor Fitzgerald 在 2023 年 12 月 17 日星期二对 Aquestive Therapeutics 的股票进行了覆盖，给予 “增持” 评级，目标价为 17.00 美元。Raymond James 在周五对 Aquestive Therapeutics 设定了 7.00 美元的目标价。Lake Street Capital 在周五将其对 Aquestive Therapeutics 的目标价从 10.00 美元下调至 8.00 美元，并给予该股票 “买入” 评级。最后，Alliance Global Partners 在周五的研究报告中重申了对 Aquestive Therapeutics 的 “买入” 评级。八位研究分析师对该股票给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，Aquestive Therapeutics 目前的共识评级为 “买入”，共识目标价为 10.57 美元。</p>
<p><strong>阅读我们对 Aquestive Therapeutics 的最新股票分析</strong></p>
<h2>Aquestive Therapeutics 股票表现</h2>
<p>纳斯达克代码：AQST 的股票在周二开盘价为 2.54 美元。该公司的 50 日移动平均线为 3.07 美元，200 日移动平均线为 4.09 美元。Aquestive Therapeutics 的 1 年最低价为 2.24 美元，1 年最高价为 6.23 美元。该股票的市值为 2.5113 亿美元，市盈率为-5.64，贝塔值为 2.76。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近增加或减少了对该公司的持股。美国银行在第四季度将其在 Aquestive Therapeutics 的持股增加了 905.2%。美国银行目前拥有 690,284 股该公司的股票，价值 245.7 万美元，此前在上个季度增持了 621,614 股。State Street Corp 在第三季度将其在 Aquestive Therapeutics 的持股增加了 52.1%。State Street Corp 目前拥有 1,496,739 股该公司的股票，价值 745.4 万美元，此前在此期间购买了 512,682 股。Stifel Financial Corp 在第四季度将其在 Aquestive Therapeutics 的持股增加了 315.4%。Stifel Financial Corp 目前拥有 398,561 股该公司的股票，价值 141.9 万美元，此前在上个季度增持了 302,617 股。Harvey Capital Management Inc.在第四季度将其在 Aquestive Therapeutics 的持股增加了 1,419.3%。Harvey Capital Management Inc.目前拥有 267,390 股该公司的股票，价值 95.2 万美元，此前在此期间增持了 249,790 股。最后，Verition Fund Management LLC 在第三季度购买了价值 99.5 万美元的 Aquestive Therapeutics 新股。机构投资者和对冲基金持有该公司 32.45% 的股票。</p>
<h2>关于 Aquestive Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Aquestive Therapeutics, Inc.是一家在美国及国际上运营的制药公司。该公司市场销售 Sympazan，一种用于治疗 Lennox-Gastaut 综合症的口服可溶膜制剂；Suboxone，一种用于治疗阿片类药物依赖的舌下膜制剂；Zuplenz，一种用于治疗与化疗和术后恢复相关的恶心和呕吐的口服可溶膜制剂；以及 Azstarys，一种用于治疗注意力缺陷多动障碍的每日一次产品。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过了 Aquestive Therapeutics</li>
<li>什么使一只股票成为优秀的分红股票？</li>
<li>过去 12 个月中回购收益率极高的 3 只股票</li>
<li>万亿美元市值的意义超越了数字</li>
<li>随着经济衰退担忧加剧，三大公用事业股票强劲上涨</li>
<li>低市盈率增长股票：开启投资机会</li>
<li>隐藏的宝石：5 只低于 10 美元的股票具有巨大的增长潜力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVFTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVFTVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Aquestive Therapeutics 吗？</h2>
<p>在你考虑投资 Aquestive Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Aquestive Therapeutics 并不在名单上。</p>
<p>虽然目前分析师对 Aquestive Therapeutics 的评级为 “买入”，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AQST

<p>HC Wainwright 分析师 R. Selvaraju 预测，Aquestive Therapeutics, Inc.（NASDAQ:AQST）将在 2026 财年报告每股收益为（$0.56）。该公司维持 “买入” 评级，目标价为 $10.00。目前市场对该公司收益的共识预期为每股（$0.46）。最近，该公司报告的季度每股收益为（$0.19），未能达到预期。机构投资者已增加对该公司的持股，该公司的市值为 2.5113 亿美元，市盈率为 -5.64</p>

<p>Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - HC Wainwright issued their FY2026 earnings per share estimates for Aquestive Therapeutics in a research note issued on Monday, March 10th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.56) for the year. HC Wainwright has a &#34;Buy&#34; rating and a $10.00 price target on the stock. The consensus estimate for Aquestive Therapeutics' current full-year earnings is ($0.46) per share.</p>
<div class="lb-trans"><p>Aquestive Therapeutics, Inc.（纳斯达克代码：AQST - 免费报告）- HC Wainwright 在 2023 年 3 月 10 日星期一发布的研究报告中对 Aquestive Therapeutics 的 2026 财年每股收益进行了预测。HC Wainwright 的分析师 R. Selvaraju 预计该公司将发布每股收益（$0.56）。HC Wainwright 对该股票给予 “买入” 评级，目标价为 10.00 美元。市场普遍预计 Aquestive Therapeutics 当前全年的每股收益为（$0.46）。</p>
</div><p>Get <strong>Aquestive Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aquestive Therapeutics</strong> 的提醒：</p>
</div><p>Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The firm had revenue of $11.87 million during the quarter, compared to analyst estimates of $13.11 million.</p>
<div class="lb-trans"><p>Aquestive Therapeutics（纳斯达克代码：AQST - 获取免费报告）最近在 2023 年 3 月 5 日星期三发布了季度财报。该公司报告季度每股收益为（$0.19），低于分析师普遍预期的（$0.14），差距为（$0.05）。该公司在本季度的收入为 1187 万美元，而分析师预期为 1311 万美元。</p>
</div><p>A number of other equities research analysts also recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an &#34;overweight&#34; rating and a $17.00 price objective for the company. Raymond James set a $7.00 target price on Aquestive Therapeutics in a report on Friday. Lake Street Capital cut their price target on Aquestive Therapeutics from $10.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a report on Friday. Finally, Alliance Global Partners restated a &#34;buy&#34; rating on shares of Aquestive Therapeutics in a research report on Friday. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Aquestive Therapeutics currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $10.57.</p>
<div class="lb-trans"><p>其他一些股票研究分析师最近也对该股票发表了看法。Cantor Fitzgerald 在 2023 年 12 月 17 日星期二对 Aquestive Therapeutics 的股票进行了覆盖，给予 “增持” 评级，目标价为 17.00 美元。Raymond James 在周五对 Aquestive Therapeutics 设定了 7.00 美元的目标价。Lake Street Capital 在周五将其对 Aquestive Therapeutics 的目标价从 10.00 美元下调至 8.00 美元，并给予该股票 “买入” 评级。最后，Alliance Global Partners 在周五的研究报告中重申了对 Aquestive Therapeutics 的 “买入” 评级。八位研究分析师对该股票给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，Aquestive Therapeutics 目前的共识评级为 “买入”，共识目标价为 10.57 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Aquestive Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Aquestive Therapeutics 的最新股票分析</strong></p>
</div><h2>Aquestive Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Aquestive Therapeutics 股票表现</h2>
</div><p>Shares of NASDAQ:AQST opened at $2.54 on Tuesday. The company's fifty day moving average is $3.07 and its two-hundred day moving average is $4.09. Aquestive Therapeutics has a 1-year low of $2.24 and a 1-year high of $6.23. The stock has a market capitalization of $251.13 million, a price-to-earnings ratio of -5.64 and a beta of 2.76.</p>
<div class="lb-trans"><p>纳斯达克代码：AQST 的股票在周二开盘价为 2.54 美元。该公司的 50 日移动平均线为 3.07 美元，200 日移动平均线为 4.09 美元。Aquestive Therapeutics 的 1 年最低价为 2.24 美元，1 年最高价为 6.23 美元。该股票的市值为 2.5113 亿美元，市盈率为-5.64，贝塔值为 2.76。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its holdings in shares of Aquestive Therapeutics by 905.2% in the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock valued at $2,457,000 after acquiring an additional 621,614 shares in the last quarter. State Street Corp boosted its position in shares of Aquestive Therapeutics by 52.1% in the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company's stock valued at $7,454,000 after purchasing an additional 512,682 shares during the period. Stifel Financial Corp increased its position in shares of Aquestive Therapeutics by 315.4% in the fourth quarter. Stifel Financial Corp now owns 398,561 shares of the company's stock worth $1,419,000 after acquiring an additional 302,617 shares in the last quarter. Harvey Capital Management Inc. raised its holdings in shares of Aquestive Therapeutics by 1,419.3% during the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company's stock valued at $952,000 after acquiring an additional 249,790 shares during the period. Finally, Verition Fund Management LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter valued at $995,000. Institutional investors and hedge funds own 32.45% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该公司的持股。美国银行在第四季度将其在 Aquestive Therapeutics 的持股增加了 905.2%。美国银行目前拥有 690,284 股该公司的股票，价值 245.7 万美元，此前在上个季度增持了 621,614 股。State Street Corp 在第三季度将其在 Aquestive Therapeutics 的持股增加了 52.1%。State Street Corp 目前拥有 1,496,739 股该公司的股票，价值 745.4 万美元，此前在此期间购买了 512,682 股。Stifel Financial Corp 在第四季度将其在 Aquestive Therapeutics 的持股增加了 315.4%。Stifel Financial Corp 目前拥有 398,561 股该公司的股票，价值 141.9 万美元，此前在上个季度增持了 302,617 股。Harvey Capital Management Inc.在第四季度将其在 Aquestive Therapeutics 的持股增加了 1,419.3%。Harvey Capital Management Inc.目前拥有 267,390 股该公司的股票，价值 95.2 万美元，此前在此期间增持了 249,790 股。最后，Verition Fund Management LLC 在第三季度购买了价值 99.5 万美元的 Aquestive Therapeutics 新股。机构投资者和对冲基金持有该公司 32.45% 的股票。</p>
</div><h2>About Aquestive Therapeutics</h2>
<div class="lb-trans"><h2>关于 Aquestive Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.</p>
<div class="lb-trans"><p>Aquestive Therapeutics, Inc.是一家在美国及国际上运营的制药公司。该公司市场销售 Sympazan，一种用于治疗 Lennox-Gastaut 综合症的口服可溶膜制剂；Suboxone，一种用于治疗阿片类药物依赖的舌下膜制剂；Zuplenz，一种用于治疗与化疗和术后恢复相关的恶心和呕吐的口服可溶膜制剂；以及 Azstarys，一种用于治疗注意力缺陷多动障碍的每日一次产品。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Aquestive Therapeutics</li>
<li>What Makes a Stock a Good Dividend Stock?</li>
<li>3 Stocks With Sky-High Buyback Yields Over the Last 12 Months</li>
<li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li>
<li>Top 3 Utilities Stocks Powering Up as Recession Fears Rise</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过了 Aquestive Therapeutics</li>
<li>什么使一只股票成为优秀的分红股票？</li>
<li>过去 12 个月中回购收益率极高的 3 只股票</li>
<li>万亿美元市值的意义超越了数字</li>
<li>随着经济衰退担忧加剧，三大公用事业股票强劲上涨</li>
<li>低市盈率增长股票：开启投资机会</li>
<li>隐藏的宝石：5 只低于 10 美元的股票具有巨大的增长潜力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVFTVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=AQST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aquestive Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Aquestive Therapeutics 吗？</h2>
</div><p>Before you consider Aquestive Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Aquestive Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Aquestive Therapeutics 并不在名单上。</p>
</div><p>While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然目前分析师对 Aquestive Therapeutics 的评级为 “买入”，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

分析师对 Aquestive Therapeutic 2026 财年收益的预测